What is the ranking of Angiotensin Receptor Blockers (ARBs) by potency from highest to lowest?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The most potent angiotensin receptor blockers (ARBs) ranked in decreasing order of potency are: telmisartan, olmesartan, candesartan, valsartan, losartan, and eprosartan, based on their binding affinity to the angiotensin II type 1 (AT1) receptor and ability to maintain receptor blockade over time, as demonstrated in a study published in the International Journal of Clinical Pharmacology Research 1. The potency of an ARB is determined by its binding affinity to the AT1 receptor and its ability to maintain receptor blockade over time.

  • Key factors to consider when prescribing ARBs include the specific patient's needs, comorbidities, and the drug's pharmacokinetic properties.
  • For example, telmisartan has a long half-life, making it suitable for once-daily dosing and potentially improving adherence, as noted in a study published in Clinical and Experimental Hypertension 2.
  • Typical starting doses vary by medication:
    • Telmisartan: 40 mg once daily
    • Olmesartan: 20 mg once daily
    • Candesartan: 16 mg once daily
    • Valsartan: 40-80 mg once daily
    • Losartan: 25-100 mg once daily
  • Doses can be adjusted based on blood pressure response and tolerability, and it's crucial to monitor renal function and potassium levels when initiating or adjusting ARB therapy, especially in patients with renal impairment or those taking other medications that can affect potassium levels, as discussed in a review published in Pharmacological Reviews 3.
  • The choice of ARB should be based on the specific patient's needs, comorbidities, and the drug's pharmacokinetic properties, rather than solely on potency, as higher potency doesn't always equate to better clinical outcomes, as noted in a study published in The Canadian Journal of Cardiology 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.